NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased ImmunityBio, Inc. ("ImmunityBio") (NASDAQ:IBRX) between May 23, 2022 and May 10, 2023.
If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/immunitybio-class-action-submission-form?prid=43784&wire=1
Allegations against IBRX include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, Good Manufacturing Practice ("GMP") deficiencies at its third-party contract manufacturing organizations ("CMOs") for the antibody cytokine fusion protein N-803, commercially referred to as "Anktiva"; (ii) one or more of the Company's third-party CMOs for Anktiva did in fact suffer from GMP deficiencies; (iii) the foregoing deficiencies was likely to cause the FDA to reject the Anktiva Biologics License Application ("BLA") in its present form; (iv) accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you suffered a loss in ImmunityBio you have until August 29, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong